| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
In the small intestine, most triglycerides are broken down into monoglycerides, free fatty acids, and glycerol, and absorbed by the intestinal mucosa. Within the intestinal epithelial cells, resynthesized triglycerides aggregate with cholesterol and phospholipids to form globular structures, which are then encapsulated by proteins, forming chylomicrons. Chylomicrons are transported via the lymphatic system to the thoracic duct and eventually into the venous system. Chylomicrons are cleared from the bloodstream as they flow through the capillaries of adipose tissue. Fat is stored in adipocytes until it is transported to other tissues as free fatty acids for cellular energy metabolism or cell membrane synthesis. Following intravenous injection of 14C-labeled long-chain triglycerides, 25% to 30% of the radiolabeled material appears in the liver within 30 to 60 minutes, with less than 5% remaining after 24 hours. Small amounts of radiolabeled material are also found in the spleen and lungs. After 24 hours, nearly 50% of the radiolabeled material is excreted with carbon dioxide, leaving only 1% of the carbon-labeled material in brown adipose tissue. The radioactivity concentration in epididymal fat is less than half that of brown fat. After absorption, long-chain saturated fatty acids are primarily transported via the intestinal lymphatic system in the form of triglycerides. Fatty acids with 10 or fewer carbon atoms are primarily transported from the intestine via the portal vein. Data also indicate that unsaturated long-chain fatty acids are primarily absorbed via the lymphatic system. In vivo experiments in Wistar rats and in vitro experiments in hairless female mice have demonstrated that caprylic acid glycerides enhance drug permeability through the skin. …In the presence of triglycerides, drug permeability increases in the following order: caprylic acid glycerides (C8) > trioleic acid glycerides (C18) > tributyric acid glycerides (C4) > triacetin (C2). |
|---|---|
| Toxicity/Toxicokinetics |
Non-Human Toxicity Values
LD50: Rat (female) 33.3 g/kg LD50: Rat (male) oral 34.2 g/kg LD50: Mouse (female) oral 29.6 g/kg LD50: Mouse (male) oral 34.2 g/kg LD50: Mouse (intravenous) 3,700 ± 194 mg/kg |
| References | |
| Additional Infomation |
Tricaprylyl glycerol is an odorless, viscous, transparent, colorless to amber-brown liquid. (NTP, 1992)
Tricaprylyl glycerol is a triglyceride obtained by acylation of the three hydroxyl groups of glycerol with caprylic acid. It can be used as a glucose alternative energy source for patients with mild to moderate Alzheimer's disease. It has anticonvulsant effects and is also a plant metabolite. It is a triglyceride and caprylic acid ester. Tricaprylyl glycerol has been used in research trials for supportive care and treatment of Alzheimer's disease. |
| Molecular Formula |
C27H50O6
|
|---|---|
| Molecular Weight |
470.69
|
| Exact Mass |
470.36
|
| CAS # |
538-23-8
|
| PubChem CID |
10850
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
508.0±17.0 °C at 760 mmHg
|
| Melting Point |
9-10 °C
|
| Flash Point |
209.3±21.0 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.458
|
| LogP |
9.33
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
33
|
| Complexity |
461
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)C([H])(C([H])([H])OC(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)C([H])([H])OC(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
VLPFTAMPNXLGLX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H50O6/c1-4-7-10-13-16-19-25(28)31-22-24(33-27(30)21-18-15-12-9-6-3)23-32-26(29)20-17-14-11-8-5-2/h24H,4-23H2,1-3H3
|
| Chemical Name |
2,3-di(octanoyloxy)propyl octanoate
|
| Synonyms |
tricaprylic glyceride; trioctanoin; Tricaprilin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~41.67 mg/mL (~88.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1245 mL | 10.6227 mL | 21.2454 mL | |
| 5 mM | 0.4249 mL | 2.1245 mL | 4.2491 mL | |
| 10 mM | 0.2125 mL | 1.0623 mL | 2.1245 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
